Literature DB >> 12490396

Epstein-Barr virus latent membrane protein-1 induction by histone deacetylase inhibitors mediates induction of intercellular adhesion molecule-1 expression and homotypic aggregation.

Jae Hong Park1, Douglas V Faller.   

Abstract

Epstein-Barr virus (EBV) latent membrane protein (LMP)-1 induces B lymphocyte immortalization and activates constitutive signal transduction, including NF-kappaB, JNK/p38, and JAK/STAT pathways. During EBV latency, LMP-1 expression induces several B lymphocyte activation markers, including intercellular adhesion molecule (ICAM)-1. We found that various structurally distinct histone deacetylase inhibitors (HDACI), as well as phorbol ester treatment, induced homotypic aggregation in EBV-positive Burkitt's lymphoma lines. Cell-surface expression of ICAM-1 was concurrently strongly up-regulated by both HDACI and phorbol ester treatments. Cell-surface expression of ICAM-1 was concurrently strongly induced by both HDACI and phorbol ester treatment. Among several ICAM family members, only ICAM-1 was up-regulated by both HDACI and phorbol ester treatments, suggesting that up-regulated ICAM-1 expression might mediate the observed increase in homotypic aggregation. HDACI-induced homotypic aggregation was blocked by exposure to a monoclonal antibody specific for the beta-chain (CD18) of an ICAM-1 ligand, LFA-1. Unexpectedly, HDAC inhibition, but not phorbol ester treatment, induced LMP-1 expression in EBV-positive cell lines, and this LMP-1 species was identified by RT-PCR and immunoblot analyses as the latent form of LMP-1. Control of EBV LMP-1 gene expression by HDACI inhibition occurs at the transcriptional level, as indicated by nuclear runoff studies and analysis of steady-state mRNA levels. Dominant-negative LMP-1 efficiently blocked HDACI-induced ICAM-1 up-regulation, and ectopic expression of LMP-1 activated expression of an ICAM-1 promoter-driven reporter gene. The HDACI-induced up-regulation of ICAM-1, and consequent homotypic aggregation, were efficiently blocked by the addition of N-acetyl-L-cysteine and by ectopic expression of a super-repressor IkappaBalpha, while LPM-1 induction was unaffected, suggesting that these effects are mediated by NF-kappaB. We demonstrate, therefore, that the latent isoform of LMP-1 is induced by HDAC inhibition, and that HDACI-induced latent LMP-1 expression, through NF-kappaB activation, is responsible for ICAM-1 expression up-regulation and homotypic adhesion.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12490396     DOI: 10.1006/viro.2002.1638

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  10 in total

1.  A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies.

Authors:  Susan P Perrine; Olivier Hermine; Trudy Small; Felipe Suarez; Richard O'Reilly; Farid Boulad; Joyce Fingeroth; Melissa Askin; Arthur Levy; Steven J Mentzer; Massimo Di Nicola; Alessandro M Gianni; Christoph Klein; Steven Horwitz; Douglas V Faller
Journal:  Blood       Date:  2006-11-21       Impact factor: 22.113

2.  Upregulation of STAT3 marks Burkitt lymphoma cells refractory to Epstein-Barr virus lytic cycle induction by HDAC inhibitors.

Authors:  Derek Daigle; Cynthia Megyola; Ayman El-Guindy; Lyn Gradoville; David Tuck; George Miller; Sumita Bhaduri-McIntosh
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

3.  Essential role for protein kinase D family kinases in the regulation of class II histone deacetylases in B lymphocytes.

Authors:  Sharon A Matthews; Ping Liu; Martin Spitaler; Eric N Olson; Timothy A McKinsey; Doreen A Cantrell; Andrew M Scharenberg
Journal:  Mol Cell Biol       Date:  2006-02       Impact factor: 4.272

4.  Short, discontinuous exposure to butyrate effectively sensitizes latently EBV-infected lymphoma cells to nucleoside analogue antiviral agents.

Authors:  Sajal K Ghosh; Lora W Forman; Idowu Akinsheye; Susan P Perrine; Douglas V Faller
Journal:  Blood Cells Mol Dis       Date:  2006-12-11       Impact factor: 3.039

5.  Autoactivation of the Epstein-Barr virus oncogenic protein LMP1 during type II latency through opposite roles of the NF-kappaB and JNK signaling pathways.

Authors:  Gautier Goormachtigh; Tan-Sothéa Ouk; Alexandra Mougel; Denis Tranchand-Bunel; Eric Masy; Christophe Le Clorennec; Jean Feuillard; Georg W Bornkamm; Claude Auriault; Evelyne Manet; Véronique Fafeur; Eric Adriaenssens; Jean Coll
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

6.  Tubacin kills Epstein-Barr virus (EBV)-Burkitt lymphoma cells by inducing reactive oxygen species and EBV lymphoblastoid cells by inducing apoptosis.

Authors:  Junichi Kawada; Ping Zou; Ralph Mazitschek; James E Bradner; Jeffrey I Cohen
Journal:  J Biol Chem       Date:  2009-04-22       Impact factor: 5.157

7.  Upregulation of LMP1 expression by histone deacetylase inhibitors in an EBV carrying NPC cell line.

Authors:  Jun Nishikawa; Lorand L Kis; Anquan Liu; Xiangning Zhang; Miki Takahara; Kentaro Bandobashi; Csaba Kiss; Noemi Nagy; Kiwamu Okita; George Klein; Eva Klein
Journal:  Virus Genes       Date:  2004-01       Impact factor: 2.332

8.  Histone deacetylases in viral infections.

Authors:  Georges Herbein; Daniel Wendling
Journal:  Clin Epigenetics       Date:  2010-05-30       Impact factor: 6.551

9.  Advances in Virus-Directed Therapeutics against Epstein-Barr Virus-Associated Malignancies.

Authors:  Sajal K Ghosh; Susan P Perrine; Douglas V Faller
Journal:  Adv Virol       Date:  2012-03-05

10.  Phosphorylated ezrin is associated with EBV latent membrane protein 1 in nasopharyngeal carcinoma and induces cell migration.

Authors:  K Endo; S Kondo; J Shackleford; T Horikawa; N Kitagawa; T Yoshizaki; M Furukawa; Y Zen; J S Pagano
Journal:  Oncogene       Date:  2009-02-23       Impact factor: 9.867

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.